Travere therapeutics reports first quarter 2025 financial results

San diego--(business wire)-- #1q25earnings--travere therapeutics, inc. (nasdaq: tvtx) today reported its first quarter 2025 financial results and provided a corporate update. “as the only fully approved, kidney-targeted therapy that has demonstrated superior efficacy in a head-to-head trial, filspari is elevating the standard of care in igan. our strong start to the year reflects this leadership – in the first quarter, we delivered 13% sequential net sales growth for filspari in the u.s., driven by sustained d.
TVTX Ratings Summary
TVTX Quant Ranking